Equities

Medical Developments International Ltd

Medical Developments International Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.40
  • Today's Change-0.005 / -1.23%
  • Shares traded58.67k
  • 1 Year change-46.31%
  • Beta2.0490
Data delayed at least 20 minutes, as of Jun 17 2024 06:48 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Medical Developments International Limited is an Australia-based company that delivers emergency medical solutions dedicated to improving patient outcomes in both domestic and international markets. The Company operates in two segments: Pain Management and Respiratory. The Pain Management segment is engaged in the supply of analgesia for acute and procedural pain. The Company manufactures inhaled analgesic, Penthrox (the Green Whistle), at manufacturing facilities at Scoresby and Springvale in Victoria, Australia. Penthrox is sold into domestic and international markets through distribution partnerships and direct in-market capability. The Respiratory segment is a supplier of respiratory products including asthma and chronic obstructive pulmonary disease (COPD) space chambers, peak flow meters, portable nebulizers and silicone face masks. Respiratory supplies into Australia, the United States of America, Europe, and Asia through partnerships with distributors.

  • Revenue in AUD (TTM)33.49m
  • Net income in AUD-19.21m
  • Incorporated2003
  • Employees68.00
  • Location
    Medical Developments International Ltd4 Caribbean Drive, ScoresbyMELBOURNE 3179AustraliaAUS
  • Phone+61 39547-1888
  • Fax+61 39547-0262
  • Websitehttps://www.medicaldev.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zeo Scientifix Inc7.02m-8.68m17.59m23.00------2.51-0.8249-0.82490.6729-0.24621.381.8830.66201,828.30-170.08-371.43----87.8988.28-123.65-200.710.4017-14.47-----29.7836.4321.47--40.91--
Ecofibre Ltd28.78m-67.07m18.94m----0.5968--0.6583-0.1926-0.19490.08330.08380.26830.914510.84---62.65-8.68-72.33-9.3673.6164.01-233.47-23.851.53-0.38950.4516--7.5841.41-172.07---4.37--
China Ever Grand Financl Lasng Gp Co Ltd10.20m-7.82m20.90m62.00--0.2384--2.05-0.024-0.02290.03120.26840.08082.133.59850,032.30-6.20-9.34-8.31-16.1733.728.95-76.67-140.711.59-227.390.00---26.54-10.25-27.68---22.87--
Multi Indocitra Tbk PT100.82m2.96m25.00m404.008.340.29865.000.247954.1954.191,847.861,513.980.85711.605.222,762,183,000.002.512.853.704.0146.0650.652.933.690.76172.710.2496--11.4911.24-27.970.8175-21.71--
Liberta Co Ltd71.00m-67.65k30.79m118.00--2.2122.120.4337-2.34-2.342,487.28482.671.202.677.6562,643,520.00-0.10683.75-0.21696.4238.2441.81-0.08912.370.82473.150.694835.676.779.76-2.77-12.8523.12--
Exceed World Inc34.70m-2.00m30.89m41.00--1.28--0.8903-0.0405-0.04050.7020.48730.895310.42424.59559,890.50-5.174.14-7.276.1750.1948.99-5.774.023.01-622.740.0019---25.27-5.76-113.33---31.13--
Medical Developments International Ltd33.49m-19.21m34.95m68.00--0.4618--1.04-0.2226-0.22260.38820.8770.33481.016.18---19.20-6.67-22.18-7.4369.6469.90-57.36-23.551.93--0.0311--47.3713.1254.79---6.41--
Delko SA333.43m6.19m36.31m1.16k5.870.63182.990.10891.401.4075.4813.012.650.168011.04--4.93--8.46--98.30--1.86--0.7361849.720.3958--------------
BIMI Holdings Inc19.10m-15.90m44.42m296.001.461.61--2.331.441.592.631.300.37131.812.2542,677.87-31.04-38.59-77.82-88.9340.3034.59-83.60-135.610.8572-24.660.1134---44.516.8237.56------
Penta Valent Tbk PT244.94m3.76m46.54m--12.252.0810.860.1923.3623.361,525.15137.393.068.956.37--4.69--15.53--12.01--1.54--0.925811.070.2678--15.71--53.62------
Rhone Ma Holdings Bhd66.03m3.90m48.89m--17.080.92978.730.74050.04040.04040.68420.74220.94242.934.98--6.266.157.477.3826.4028.116.646.852.9113.360.14432.112.418.46-5.163.72-27.03-7.79
EZZ Life Science Holdings Ltd43.71m3.47m52.41m--14.503.2913.831.200.08140.08141.020.35822.489.6313.51--19.6921.2224.8529.1974.7755.317.949.113.61293.270.019513.08147.26--176.57------
Data as of Jun 17 2024. Currency figures normalised to Medical Developments International Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

12.22%Per cent of shares held by top holders
HolderShares% Held
FIL Investment Management (Hong Kong) Ltd.as of 13 Mar 20244.70m5.45%
Netwealth Investments Ltd.as of 11 Sep 20232.73m3.16%
FIL Investment Management (Australia) Ltd.as of 22 Jan 20242.70m3.13%
Dimensional Fund Advisors LPas of 31 Jan 2024173.84k0.20%
DFA Australia Ltd.as of 30 Apr 2024141.34k0.16%
FIL Investment Management (Singapore) Ltd.as of 11 Sep 202377.96k0.09%
Dimensional Fund Advisors Ltd.as of 30 Apr 202415.27k0.02%
More ▼
Data from 31 Mar 2024 - 13 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.